Imovax Polio

Poliovirus (Inactivated) Type 2 and Type 3, the active ingredient in Imovax Polio, is a vaccine presented as an unspecified strength/vial for intramuscular, subcutaneous use. It prevents poliomyelitis caused by poliovirus types 1, 2, and 3 in individuals at risk.

GNH USA supplies Imovax Polio as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imovax Polio is an inactivated poliovirus vaccine used to induce protective immunity against poliovirus infection. - Poliomyelitis (polio): Provides active immunity to prevent infection by poliovirus types 1, 2, and 3 in children and adults. - Travel to endemic regions: Reduces the risk of poliovirus exposure for travelers visiting areas with ongoing transmission. - Outbreak response: Supports mass immunization campaigns to control and eradicate poliovirus spread during public health emergencies.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the site of administration. - Redness or swelling: localized erythema or edema that resolves within a few days. - Fever: low‑grade temperature elevation occurring within 24‑48 hours. - Headache: transient headache reported after vaccination. - Fatigue: temporary feeling of tiredness. - Myalgia: mild muscle aches.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare autoimmune neuropathy that may develop weeks after vaccination. - Seizures: infrequent neurologic events, especially in children with pre‑existing conditions. - Severe hypotension: marked drop in blood pressure post‑injection. - Acute allergic edema: swelling of face, lips, or airway.

Before administering Imovax Polio, consider the following precautions: - Severe allergy: Do not vaccinate individuals with known hypersensitivity to any vaccine component. - Acute illness: Postpone vaccination in persons with moderate or severe febrile illness. - Immunocompromised status: Evaluate immune function; vaccine may be less effective. - Pregnancy: Discuss risk‑benefit with a healthcare professional before use. - Breastfeeding: Weigh potential benefits against unknown risks. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Imovax Polio may interact with other medical products as follows: Major Interactions (Avoid): - Live attenuated vaccines: Avoid co‑administration within four weeks to prevent interference. - Immunoglobulin therapy: May reduce vaccine efficacy if given within two weeks before or after vaccination. - Blood products: Concurrent transfusion can impair immune response. Moderate Interactions (Monitor Closely): - Antipyretics (e.g., acetaminophen, ibuprofen): May mask fever but do not affect immunogenicity. - Immunosuppressive drugs: May diminish antibody production; monitor serologic response.